Frodl et al. carried out an DNAm-MRI analysis with medication status as a covariate, and but found that this did not modify their findings regarding SLC6A4 methylation and brain function in MDD patients and controls, while Booij et al. have reported differential methylation at the SLC6A4 promoter in association SSRI exposure (Booij et al., 2015; Frodl et al., 2015). The gene discussed is SLC6A4; the disease is major depressive disorder.